A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers

drug protocol number
CT18/004/R
drug sponsor
KAIMRC
drug study
vaccine ChAdOx1 MERS
drug trial site
NGHA-R
drug status
Ongoing
drug phase